5-azacytidine
Recurrent Histiocytic and Dendritic Cell Neoplasm
National Cancer Institute (NCI)Phase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 95/ 100
Competitive context
5 Active assets in the Recurrent Histiocytic and Dendritic Cell Neoplasm cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Selpercatinib National Cancer Institute (NCI) | Phase 2 | CCC |
Ulixertinib National Cancer Institute (NCI) | Phase 2 | CCC |
s241656 Institut de Recherches Internationales Servier | Phase 1/2 | CCC |
Cetuximab Institut de Recherches Internationales Servier | Phase 1/2 | CCC |
PANITUMUMAB Institut de Recherches Internationales Servier | Phase 1/2 | CCC |
Choline Salicylate Mayo Clinic | Phase 1 | CC |
Selinexor Mayo Clinic | Phase 1 | CC |
Same molecule, other indications
5-azacytidine is also rated in:
Acute Myeloid Leukaemia; Myelodysplastic Syndromes;Chronic Myelomonocytic LeukemiaDormant
BB
Indicative ·
65 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →